secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001367644-23-000148
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions cuts 400 jobs, eliminates COO role in restructuring to focus on core MCM and NARCAN
--------------------------------------------------------------------------------

- Plan reduces workforce by ~400 employees; charges of $19M-$21M expected in Q3 2023.
- Annualized cost savings targeted >$100M; CDMO services investment de-emphasized.
- COO role eliminated; Adam Havey leaves Sep 30, 2023; Bill Hartzel takes over manufacturing ops.
- Operations reduced at Bayview (Baltimore) and Canton (MA) facilities; maintained for demand response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/0001367644-23-000148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000148/ebs-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer